Recovery Act Limited Competition Research to Address the Heterogeneity in Autism Spectrum Disorders (R21) | Apply Online

Frequently Asked Questions (FAQs)

What is the title and funding opportunity number for this grant?

The opportunity is titled "Recovery Act Limited Competition Research to Address the Heterogeneity in Autism Spectrum Disorders (R21)" and the Funding Opportunity Number is RFA-MH-09-172.

What agency offered this funding opportunity?

This was an NIH (National Institutes of Health) grant opportunity.

What was the main purpose of this funding opportunity?

The central aim was to support research that explains why Autism Spectrum Disorders (ASD) can present so differently across individuals. The focus was on breaking down ASD heterogeneity by improving measurement, identifying distinct biological and behavioral subtypes, and clarifying different pathways that may lead to ASD-related outcomes.

What does "heterogeneity in ASD" mean in the context of this FOA?

In this context, heterogeneity refers to the meaningful variability in ASD across people, such as differences in symptom profiles, developmental trajectories, functioning, underlying biology, treatment response, and service needs. The FOA sought studies that move beyond one-size-fits-all descriptions toward evidence-based ways to characterize subgroups and mechanisms.

What type of grant mechanism was used?

This opportunity used the NIH Exploratory/Developmental Research Grant (R21) mechanism.

Why did the R21 mechanism matter for this announcement?

The R21 is designed for early-stage, high-potential ideas where extensive preliminary data may not yet be available. The FOA emphasized rapid testing of innovative concepts, initial technical development, proof of principle, feasibility data generation, or validating early signals that could justify larger future studies.

What scientific areas and topics were encouraged?

The FOA encouraged a broad range of approaches aimed at understanding ASD variability, including measurement development, biomarkers/biological signatures, immune and central nervous system interactions, genetics and genomics, environmental risk factors, and model development (animal, cellular, computational, or other models). It also welcomed exploratory research on treatment and intervention, and services research related to how differences among individuals with ASD affect service use, access, outcomes, and system-level planning.

What kinds of measurement development projects were relevant?

Examples included developing or improving tools to better capture symptom profiles, developmental trajectories, functioning, and treatment response in ways that help distinguish subgroups within ASD.

What did the FOA mean by biomarkers or biological signatures?

The FOA described biomarkers/biological signatures as signals that might help indicate ASD subtype, prognosis, or likely benefit from an intervention.

Did the FOA encourage research on immune system and brain interactions?

Yes. Priority topics included research exploring how immune processes may relate to central nervous system development and behavior in ways that could contribute to ASD heterogeneity.

Was genetics and genomics research within scope?

Yes. The FOA encouraged genetics and genomics approaches, including studying risk variants and how genetic findings map to differences in phenotype.

Were environmental risk factors part of the encouraged scope?

Yes. The announcement included environmental risk factors, such as exposures that might interact with genetic vulnerability to influence ASD-related outcomes and variability.

What types of models were considered relevant?

The FOA welcomed model development, including animal, cellular, computational, or other models used to test mechanisms that may underlie ASD heterogeneity.

Did this opportunity include treatment and intervention research?

Yes. The FOA welcomed exploratory treatment and intervention research, particularly work that could inform more targeted or personalized approaches.

Did this opportunity include services research?

Yes. Services research was encouraged when focused on how individual differences in ASD affect service use, access, outcomes, and system-level planning.

Was this a Recovery Act (ARRA) funded program?

Yes. This NIH opportunity was created with American Recovery and Reinvestment Act of 2009 (ARRA) funds.

How much funding was NIH planning to commit to this initiative?

NIH planned to commit approximately $57,000,000 across this FOA and its companion announcements.

How many awards were anticipated?

The anticipated total was about 40 to 50 awards, depending on application volume, scientific merit, and funds availability.

Was this funding limited to this FOA only?

No. The $57,000,000 figure was planned across this FOA and its companion announcements that covered the same overall scientific scope but used different grant mechanisms.

What were the key dates for this opportunity?

The opportunity was posted on March 23, 2009. The closing date was May 12, 2009. It was later archived on June 12, 2009.

Is this funding opportunity still open?

No. Based on the provided information, it closed on May 12, 2009 and was archived on June 12, 2009.

What CFDA number was associated with this opportunity?

The opportunity fell under CFDA 93.701 (Trans-NIH Recovery Act Research Support).

Did the FOA require cost sharing or matching funds?

No. The FOA did not require cost sharing or matching.

Who was eligible to apply?

Eligibility was broad and included many types of organizations across academia, government, nonprofit, and industry, as long as the proposed work fit the exploratory R21 scope and addressed ASD heterogeneity within the scientific areas described.

Were universities and colleges eligible?

Yes. Eligible applicants included public and private institutions of higher education.

Were nonprofit organizations eligible?

Yes. Nonprofits with or without 501(c)(3) status were eligible (with specific conditions noted in the original eligibility framing).

Were businesses eligible to apply?

Yes. Small businesses and other for-profit organizations (beyond small businesses) were included as eligible applicants.

Were government entities eligible?

Yes. Eligibility included state, county, city/township, special district governments, and independent school districts, as well as eligible federal agencies.

Were tribal governments and tribal organizations eligible?

Yes. The eligibility list explicitly included tribal governments and tribal organizations.

Were public housing authorities eligible?

Yes. Public housing authorities and Indian housing authorities were listed as eligible.

Were U.S. territories or possessions included in eligibility?

Yes. U.S. territories or possessions were included among eligible applicants.

Were minority-serving institutions and specialized institution types mentioned?

Yes. The FOA explicitly included categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Alaska Native and Native Hawaiian Serving Institutions, and Tribally Controlled Colleges and Universities (TCCUs).

Were faith-based and community-based organizations eligible?

Yes. Faith-based or community-based organizations were included.

Were regional organizations eligible?

Yes. Regional organizations were listed among eligible applicants.

What other NIH opportunities were mentioned as companions to this R21 announcement?

NIH positioned this R21 alongside companion announcements covering the same scientific scope but different mechanisms: RFA-MH-09-173 (R34, including collaborative R34 projects) and RFA-MH-09-170 and RFA-MH-09-171 (R01 and collaborative R01 mechanisms for larger, more comprehensive studies).

How did the companion R34 announcement differ from this R21?

RFA-MH-09-173 used the R34 (Clinical Exploratory/Developmental Grant) mechanism and was geared toward early phases of treatment development, including collaborative R34 projects, while this FOA used the R21 mechanism for exploratory/developmental research.

How did the companion R01 announcements differ from this R21?

The referenced R01 and collaborative R01 announcements (RFA-MH-09-170 and RFA-MH-09-171) were intended for larger projects that already had a stronger evidence base or preliminary findings, whereas this R21 emphasized exploratory, early-phase work.

What overall impact was NIH aiming for with this Recovery Act effort?

The FOA was designed as a time-limited Recovery Act initiative to accelerate innovative, early-phase research that could identify meaningful differences within the autism spectrum, improve tools and indicators for subgroup identification, clarify biological and environmental mechanisms behind variability, and lay groundwork for more tailored interventions and more effective services.